MoonLake Immunotherapeutics (MLTX) EBIT (2021 - 2026)

MoonLake Immunotherapeutics' EBIT history runs 6 years deep, the most recent figure standing at -$70.0 million for Q1 2026.

• In Q1 2026, EBIT fell 47.47% year-over-year to -$70.0 million; the TTM figure through Mar 2026 stood at -$267.4 million (down 56.58% YoY), while the FY2025 annual figure was -$244.8 million, down 71.1% from the prior year.
• EBIT was -$70.0 million for Q1 2026 at MoonLake Immunotherapeutics, down from -$65.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$12.9 million in Q1 2023 to a low of -$71.4 million in Q3 2025.
• Historically, EBIT has averaged -$33.9 million across 5 years, with a median of -$19.8 million in 2024.
• Biggest YoY gain for EBIT was 68.84% in 2022; the steepest drop was 16840.81% in 2022.
• A 5-year view of EBIT shows it stood at -$16.7 million in 2022, then gained by 9.99% to -$15.0 million in 2023, then slumped by 229.9% to -$49.6 million in 2024, then slumped by 31.54% to -$65.2 million in 2025, then fell by 7.37% to -$70.0 million in 2026.
• The last three EBIT figures came in at -$70.0 million (Q1 2026), -$65.2 million (Q4 2025), and -$71.4 million (Q3 2025), per Business Quant data.